Geron Corporation (Nasdaq:GERN) will announce its financial results for the 2009 first quarter on Wednesday, April 29, 2009, after the closing of the equity market. Thomas B. Okarma, Ph.D., M.D., Geron’s president and chief executive officer, and David L. Greenwood, Geron’s executive vice president and chief financial officer, will host a conference call for analysts and investors on Thursday, April 30 at 8:00 a.m. Pacific Time, 11:00 a.m. Eastern Time.

Participants can access the conference call live via telephone by dialing 800-299-9630 (U.S.); 617-786-2904 (international). The passcode is 43754008. A live audio-only webcast is also available through a link that is posted on the Conferences page in the Investor Relations section of Geron’s Web site at http://www.geron.com. The audio Web broadcast of the conference call will be available for replay through May 29, 2009.

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell (hESC)-based therapeutics. The company has received FDA clearance to begin the world’s first human clinical trial of a hESC-based therapy: GRNOPC1 for acute spinal cord injury. For more information, visit www.geron.com.